Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Rapid Therapeutic Science Laboratories, Inc. (RTSL) Convertible Debt (2018 - 2023)

Rapid Therapeutic Science Laboratories' Convertible Debt history spans 6 years, with the latest figure at $150000.0 for Q2 2023.

  • For Q2 2023, Convertible Debt changed 0.0% year-over-year to $150000.0; the TTM value through Jun 2023 reached $150000.0, changed 0.0%, while the annual FY2022 figure was $150000.0, 0.0% changed from the prior year.
  • Convertible Debt for Q2 2023 was $150000.0 at Rapid Therapeutic Science Laboratories, roughly flat from $150000.0 in the prior quarter.
  • Across five years, Convertible Debt topped out at $2.2 million in Q1 2019 and bottomed at $150000.0 in Q1 2021.
  • The 5-year median for Convertible Debt is $150000.0 (2021), against an average of $545900.0.
  • The largest annual shift saw Convertible Debt changed 0.0% in 2019 before it plummeted 85.67% in 2020.
  • A 5-year view of Convertible Debt shows it stood at $465240.0 in 2019, then tumbled by 32.24% to $315240.0 in 2020, then plummeted by 52.42% to $150000.0 in 2021, then changed by 0.0% to $150000.0 in 2022, then changed by 0.0% to $150000.0 in 2023.
  • Per Business Quant, the three most recent readings for RTSL's Convertible Debt are $150000.0 (Q2 2023), $150000.0 (Q1 2023), and $150000.0 (Q4 2022).